Read more

May 19, 2023
1 min read
Save

Top in allergy/asthma: Epinephrine nasal spray; immunotherapies for multiple foods

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

An FDA advisory committee voted in support of ARS Pharmaceuticals’ neffy nasal spray for anaphylaxis in adults and children, saying available data on the epinephrine spray indicate a favorable benefit-risk assessment.

The spray’s safety profile and pharmacokinetic data were comparable with injection, according to a company press release. In addition, pharmacodynamic responses, including systolic BP and heart rate, were comparable or greater than intramuscular injection responses, even after 1 minute of dosing. It was the top story in allergy/asthma last week.

Peanuts in a bowl
Single-food oral immunotherapy and simultaneous OITs for multiple foods both were safe and feasible via established protocols, data show. Image: Adobe Stock

Another top story reported study results deeming simultaneous oral immunotherapies for multiple foods to be safe and feasible, with 68% of patients achieving maintenance for all of their allergens.

Read these and more top stories in allergy/asthma below:

FDA advisory committee votes in support of epinephrine nasal spray for anaphylaxis

The U.S. FDA Pulmonary-Allergy Drug Advisory Committee said available data support a favorable benefit-risk assessment for ARS Pharmaceuticals’ neffy nasal spray in treating anaphylaxis in adults and in children who weigh at least 30 kg. Read more.

Simultaneous oral immunotherapies for multiple foods deemed safe, feasible

Single-food oral immunotherapy and simultaneous OITs for multiple foods both were safe and feasible via established protocols, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.

Q&A: Dupilumab improves eosinophilic esophagitis outcomes for up to 52 weeks

Adolescents and adults experienced sustained improvements in eosinophilic esophagitis outcomes with dupilumab for up to 52 weeks, according to research presented at Digestive Disease Week 2023 in Chicago. Read more.

Caesarean delivery associated with atopic dermatitis in young children

Children born by caesarean section had an increased risk for developing atopic dermatitis before age 5 years compared with children born by vaginal delivery, according to a study published in Pediatric Allergy and Immunology. Read more.

Oil, gas production air pollution impacts thousands of asthma cases, exacerbations

Air pollution from oil and gas production contributed to 7,500 excess deaths, 410,000 asthma attacks and 2,200 new cases of childhood asthma across the nation in 2016, according to a study published in Environmental Research: Health. Read more.